Newsroom - Page 5

Study finds there is little evidence to suggest that an oxycodone HCI extended-release tablets nonformulary restriction has a direct effect on patient enrollment behavior.
A small phase 1b trial of pembrolizumab in patients with small-cell lung cancer shows that the immunotherapy drug had a favorable safety profile and demonstrated “promising” antitumor activity.
Coverage of our peer-reviewed research in the healthcare and mainstream press.
This week, the top managed care articles included a report from the Congressional Budget Office on the impact of eliminating the cost-sharing reduction payments; a decision from CMS to eliminate 2 mandatory bundled payment programs; and a new value-based alliance that called for ending use of a test for diagnosing heart attacks.
A free-market system with competition should lead to reduced prices and savings—theoretically. In the case of healthcare, being able to shop around for the best priced service or product not only isn’t easy, but isn’t always feasible.
There are 2 paths forward for addressing rising drug prices, but both have their unique challenges, said Darius Lakdawalla, PhD, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the School of Pharmacy at the University of Southern California.
A cardiovascular outcomes trial has already shown a reduction in cardiovascular events, but not deaths.
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST